

# John B Liao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3841225/publications.pdf>

Version: 2024-02-01

16  
papers

385  
citations

840776

11  
h-index

1125743

13  
g-index

16  
all docs

16  
docs citations

16  
times ranked

763  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgical and oncologic outcomes after robotic radical hysterectomy as compared to open radical hysterectomy in the treatment of early cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e82.	2.2	93
2	Clinical predictors of bevacizumab-associated gastrointestinal perforation. <i>Gynecologic Oncology</i> , 2011, 120, 464-469.	1.4	40
3	Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2019, 153, 217-222.	1.4	38
4	Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. <i>Gynecologic Oncology</i> , 2017, 147, 291-295.	1.4	35
5	Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. <i>Gynecologic Oncology</i> , 2015, 137, 430-435.	1.4	32
6	Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer. , 2015, 3, 16.		24
7	Gynecologic cancers and solid organ transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 1266-1277.	4.7	24
8	Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2017, 21, 78-80.	0.6	18
9	Therapeutic vaccines for ovarian cancer. <i>Gynecologic Oncology</i> , 2013, 130, 667-673.	1.4	16
10	Route of hysterectomy and surgical outcomes from a statewide gynecologic oncology population: is there a role for vaginal hysterectomy?. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 348.e1-348.e9.	1.3	15
11	Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 480-485.	1.4	12
12	Immunotherapy for gynecologic cancers. <i>Gynecologic Oncology</i> , 2016, 142, 3-5.	1.4	11
13	Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e47.	2.2	10
14	Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. , 2021, 9, e003122.		9
15	Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses. <i>Clinical Cancer Research</i> , 2021, 27, 6405-6412.	7.0	8
16	SEX CORD-STROMAL AND GERM CELL TUMORS OF THE OVARY. , 2011, , 241-260.		0